Tag: Alliance Fund
China’s YishengBio eyes US capital markets via SPAC route
Yisheng Biopharma has abandoned its Hong Kong IPO and turned instead to the Nasdaq via the SPAC route in a deal that is expected to be sealed by the first quarter of 2023
LATEST ON VANTAGE ASIA
Knowing is half the battle
Sadaff Habib, an independent arbitrator based in Dubai, points out the major challenges in local arbitration and offers key tips for Chinese businesses
